anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
A surfactant opt. in combination with a preservative and/or a substance which acts as a bactericide or fungicide on the mucous membranes in physiological saline, can be used to treat &#34;dry nose&#34;. USE/ADVANTAGE - The surfactant can be used to treat &#34;dry nose&#34; which is responsible for a range of symptoms, including difficulty with breathing, headache, sore throat, difficulty on swallowing etc. and which can be caused by e.g. heating, house dust, smoke, poorly ventilated rooms, air conditioning, etc.. The surfactant regulates the dampness of the mucous membrane when applied to the nose and throat and clears the nose and throat of dried remnants of mucous. The surfactant can act simultaneously as preservative, bactericide or fungicide as well as moisture regulator.
Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor&#39;s parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide monomers which exhibit a radical polymerization reactivity comparable with methylmethacrylate and shrink little during polymerization.  &lt;P&gt;SOLUTION: The invention relates to cyclopropyl acrylate and a composition comprising cyclopropyl acrylate. The cyclopropyl acrylates according to the invention are particularly suitable for producing dental materials, particularly polymers and copolymers, moldings, adhesives, cement, filling materials, coating materials and composites for dental use. The cyclopropyl acrylate is mixed with an initiator for radical polymerization and preferably also with additional monomers, fillers and optionally further auxiliaries. The compositions thus obtained can be cured by radical polymerization.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:To obtain a dental magnetic alloy with a low m.p. and superior castability by adding Pd, Au and Si to Co or Ni in a specified ratio. CONSTITUTION:This dental magnetic alloy consists of, by wt., 30-73% Pd, 5- 10% Au, &lt;=5% Si and 20-60% Co or Ni. The restricted Co or Ni content adjusts the melting temp. of the alloy to &lt;=1,350 deg.C, and Co or Ni alloyed with Pd provides high corrosion resistance. The addition of Au lowers the m.p., improves the casting surface, and raises the casting accuracy. Si has the effect of improving the castability and reducing blow holes. By this composition the casting timing is easily judged.
A substance suitable for the treatment of malignant tumours such as cancer, is prepared by treating (a) female animal blood taken during a period of from a few days before to a few days after delivery or taken during the first few days of menstruation, or (b) colostrum, undiluted with water, with an excess of a substantially non-aqueous water-miscible solvent to precipitate protein bodies containing the active substance, separating the solvent from and drying the precipitate and dispersing the dried precipitate in a neutral to slightly alkaline physiological solution.  In the example, human colostrum is centrifuged to remove fat, coated to 0 DEG  C. and allowed to stand.  Absolute alcohol at 0 DEG  C. is added slowly over 10 minutes, the mixture allowed to stand at room temperature for 50 minutes and then cooled to 0 DEG  C.  The precipitate is centrifuged and alcohol removed in vacuo at 45 DEG  C.  The precipitate is eluted with physiological saline solution containing disodium phosphate, stirred with bolus alba and centrifuged.  The liquid obtained contains the active principle and can be injected, taken orally, or freeze dried to form a powder which is mixed with sterile water as required.  Kaolin or fuller&#39;s earth may be used in place of bolus alba.  The non-aqueous solvent may be absolute ethyl alcohol or acetone.  Reference is made to the Cancer Act 1939.
New cpds. of formula : (where X is O or NH; A is a branched or linear divalent alkyl or &gt;6C; R is amino aliphatic gp. or 5,6 or 7-membered N-heterocycle, opt. including a second heteroatom chosen from O, S and N), and their acid addn. salts, are prepd. by condensing trimethoxy-2,4,6-benzoic acid to the chloric acid with HXAR. - Used as antispasmodics and for digestive troubles.
PROBLEM TO BE SOLVED: To obtain an expected medical effect by adjusting the dissolved oxygen content and oxidation-reduction potential of the electrolytic water to specified values or less respectively. SOLUTION: The dissolved oxygen content and oxidation-reduction potential of this electrolytic water are adjusted to &lt;=3.0ppm, preferably &lt;=2.0ppm and more desirably &lt;=1.0ppm and to &lt;=-300mV, preferably &lt;=-500mV and more desirably &lt;=-700mV, respectively. As the electrolytic water production equipment, e.g. an equipment in which an electrolytic tank 1 is divided into an electrolytic room 5 and another electrolytic room 6 with a diaphragm 4 placed in the central part of the electrolytic tank 1, is used. Also, a voltage is applied to between two electrode plates 2 and 3 so that the current passing through an electrolyte between the electrode plates 2 and 3 is constant to perform electrolysis. As each of the electrode plates 2 and 3 placed in the electrolytic tank 1, a platinum plated titanium plate is used.  Thus, since the dissolved oxygen content in the electrolytic water is remarkably low, drinking water with which the amount of active oxygen that is a by-product of a metabolism utilizing an enzyme can be reduced and any oxidation of genes and cells can be inhibited from occurring, is produced.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition and a method for imaging β-cells in vivo, and a composition and a method for improving diagnosis and treatment of pancreas-associated diseases based on finding the delivery of a pharmaceutical agent having therapeutic value specific to pancreatic β-cells.  &lt;P&gt;SOLUTION: The composition for imaging the β-cells includes a chelating agent-antidiabetic agent conjugate and, if needed, a metal to be chelated. The composition for imaging the pancreas including the antidiabetic agent, the chelating agent and a metal ion to be chelated are disclosed. The method for treating the pancreas is also disclosed. The method includes a process for administering the composition including the antidiabetic agent, the chelating agent and the metal ion to be chelated to subjects requiring the treatment of pancreatic diseases. In the composition, the metal ion is a β-ray emitter.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The present invention discloses a compound of an chlorhexidine acetate local membrane forming gel, which comprises the components of the following weight percentages comprising 0.5 percentage to 7 percentage of alkyl cellulose, 1 percentage to 10 percentage of etherifying agent, 0.5 percentage to 5 percentage of cross linking agent,75 percentage to 90 percentage of dissolvent, 0.01 percentage to 3 percentage of chlorhexidine acetate. The cross linking agent is the saturated fat or the alcoholic acid, the chemical general formula of which is C&lt;SUB&gt;n&lt;/SUB&gt;H&lt;SUB&gt;2n+2-m-l&lt;/SUB&gt;(OH)&lt;SUB&gt;m&lt;/SUB&gt;(COOH)&lt;SUB&gt;l&lt;/SUB&gt;. Among the formula, m or n or 1 is the integer and the n is no less than m, which is no less than 2. 1 is no less than 0 and the result of m plus 1 is 4 to 8. The result of n plus 1 is 4 to 8. In the present invention, the compound of the chlorhexidine acetate local membrane forming gel is applied in the treatment of the local infection in the mucosa or the skin. A water drain protective membrane with smooth property, firm property, wear-resisting property and duration property is formed on the surface of the ulcer when the present invention is applied. Compared with all kinds of local formulation of the chlorhexidine acetate, the membrane formed by the gel compound is not likely to experience fracture, dissolution or corrosion. The membrane has properties of long maintenance time and slow releasing of the medicine. The membrane can be effectively maintained in the skin surface for over 8 hours and the membrane can be effectively maintained on the mouth mucosa surface for over 5 hours.
1,152,645. Rubella vaccine. MERCK &amp; CO. Inc. 14 July, 1967 [22 May, 1967], No. 32603/67. Heading A5B. A rubella vaccine is prepared by isolating rubella virus from clinical material by inoculation of chick embryo or grivet monkey tissue culture and incubating at 30-38‹C.; successively passing the virus through culture media to attenuate the virus at least one of such passages being in media comprising minced and trypsinised 9-11 day old decapitated and amputated chick embryo culture in a cell growth medium at 30-38‹C., each passage being followed by infectivity titrations on sample harvests taken at 2-14 day intervals, the harvests being frozen until tested and re-inoculated in a culture medium if too virulent. The serial passages may include incubations in grivet monkey kidney cultures, embryonated hen&#39;s eggs or duck embryo tissue cultures.
PURPOSE:To provide an oral solution stably containing icariin for long period by compounding a nonionic surfactant. CONSTITUTION:A nonionic surfactant, preferably 0.05-5.0wt.% of a polyoxyalkylene group-having ester or ether type surfactant such as polyoxyethylene glycol fatty acid ester or polyoxyethylene hardened castor oil is added to an oral solution containing icariin which is an active ingredient of Epimedium grandiflorum Morr var. thunbergianum and which has been reported to have functions such as antibody production-accelerating activity and sthenia tonic activity. The icariin may be prepared in the form of a tincture, solution extract, soft extract or dried extract obtained by the extraction of the Epimedium grandiflorum Morr war. thunbergianum. The oral solution is prepared in the form of a solution, emulsion or suspension, and the pH of the oral solution is preferably 2.5 to &lt; 4 especially 2.5 to 3.5.
Compositions for preventing or treating inflammatory diseases such as inflammatory diseases of the joint, multiple sclerosis, leukemia, ischemic injury or reperfusion injury, are described. A fusion protein comprising an interleukin-1 receptor antagonist (IL-1ra) with all or part of a constant domain of a heavy or light chain of human immunoglobulin at the carboxy terminus is also described. Three useful forms of IL-1ra (IL-1raa, IL-1raß and IL-1rax) and variants thereof are disclosed and described in US Patent No. 5,075,222.  Described herein are modified forms of IL-1ra.  The modified forms of IL-1ra include polypeptides in which amino acids have been deleted from, inserted into and substituted for residues within the amino acid sequence of IL-1ra. For IL-1ra addition variants, each polypeptide may include an amino- and/or carboxyl-terminus fusion ranging in length from 1&gt;100 residues.
The invention discloses an application of NADH and NMN in preparation of a drug or a health caring product for Parkinson&#39;s disease, namely, [beta]-NADH and [beta]-NMN are applied for preparing the drug or the health caring product for the Parkinson&#39;s disease, wherein the [beta]-NADH and [beta]-NMN are prepared through enzyme catalysis. The invention provides the new drug or health caring product, which is prepared from the [beta]-NADH and [beta]-NMN which is prepared in an in-vitro enzyme catalysis manner, has cost advantage and is high in purity. The drug or health caring product is used for treating the Parkinson&#39;s disease. The [beta]-NADH and the [beta]-NMN, as active components, are used for preparing the drug or the health caring product for the Parkinson&#39;s disease, wherein the particular dosage can be decided according to the severity degree of the diseases, drug application approach and relative factors. The [beta]-NADH and the [beta]-NMN themselves exist in body cells, so that the [beta]-NADH and the [beta]-NMN are high in safety as the drug or the health caring product. In addition, the NMN is a monomer molecule so that the drug or the health is significant in function and is easy to stabilize.
PURPOSE:To provide a skin external agent containing an adrenocortical hormone and hyaluronic acid. CONSTITUTION:The external agent contains an adrenocortical hormone (e.g. hydrocortisone hydrochloride) and hyaluronic acid as active ingredients. The addition of the hyaluronic acid to the skin external agent in a concentration of 0.005-0.1wt.% permits to reduce the amount of the adrenocortical hormone to &lt;= the usually used amount, such as approximately 1/2 to 1/10 of the amount. The adrenocortical hormone is useful for skin diseases such as eczema, contact dermatitis, atopic dermatitis, strophulus, urticaria, and psoriasis, but causes the adverse actions such as pituitary.adrenocortical function depression, skin infectious diseases and acne, when used as the external agent in a wide range over a long period. The addition of the hyaluronic acid enables to prepare the external agent having the excellent therapeutic effects and good in the safety and usability.
The invention relates to a traditional Chinese medicine composition for diminishing inflammation and relieving pain, which is prepared from the following raw material medicines: chinese angelica, eucommia bark, szechuan lovage rhizome, fortune&#39;s drynaria rhizome, cibotium barometz, Chinese taxillus twig, teasel root, medicinal cyathula root, costus root, cassia twig, dahurian angelica root, baical skullcap root, amur corktree bark, corydalis tuber and clematis root. The invention also provides the application of the traditional Chinese medicine composition. Its advantages are: the traditional Chinese medicine composition of the invention supplements each other, accords with the theory of traditional Chinese medicine, and can effectively diminish inflammation and relieve pain. The functional indications are as follows: relaxing muscles and tendons, promoting blood circulation, relieving inflammation, and alleviating pain. Can be used for treating acute and chronic injury, joint pain, and lumbar muscle strain. The traditional Chinese medicine composition disclosed by the invention is proved by tests to be capable of obviously improving the pain threshold of mice and has obvious curative effects on acute soft tissue injury, chronic soft tissue injury, knee joint pain and lumbar muscle strain.
A composition and method for treating both superficial and subdermal inflammation is taught by treating an inflamed skin area, muscle, or bone joint, with a therapeutically effective amount of a skin-compatible ester of a zwitterionic aminosulphonic acid (ZASA-Ester) of the formula. wherein M is an alkali metal, like sodium, and R is a naturally occurring, straight-chain, saturated or unsaturated, aliphatic acid, the esters of which form fatty acids in nature. The most useful of which are the acetic oleic (cis isomer), linoleic, palmitic, and stearic moieties; they occur naturally as glycerides, i.e., esters of glycerol. Also useful are analogs of HEPES like piperazine-N&#39;-(2-ethane sulfonic acid); N-methylpiperazine-N&#39;-(2-ethane sulfonic acid);, and the piperiodine analog of the piperazine ester. A pharmacologic composition is also provided which comprises at least one amphoteric (Zwitterionic-ester) with a pharmacologically-acceptable topical carrier or base. Other adjunctive pharmaceutical agents may be included to facilitate other than topical administration. Also useful are analogs of HEPES, like Piperazine-N1(2-ethanesulfonic acid; N-Methylpiperazine-N1(2-ethanesulfonic acid) and the piperidine analog of the piperazine ester.
A composition for treating cancer cells in a subject having an immune system, comprising a virus in the genus Yatapoxvirus (Yatapoxvirus) having at least one mutation. In one embodiment, the mutation results in the inhibition of the expression of the TNF binding protein by the virus. In another embodiment, the mutation results in suppression of thymidine kinase (&#34;TK&#34;) expression by the virus. In another embodiment, the mutation renders the virus transgenic for expression of bacterial flagellin. Mutations may be present individually or in combination. Additional aspects include methods of treating cancer cells with a composition as described herein, and methods of delivering at least one gene to cancer cells in a subject.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition containing a new protein and the use of the same for the diagnosis and treatment of immune-related diseases.  &lt;P&gt;SOLUTION: This PRO polypeptide based on the identification of a protein obtained as a result of stimulating the immunological responses of a mammalian animal is provided. Also, a method for identifying the agonist of the PRO polypeptide or the antagonist of the PRO polypeptide is provided. A medicine and a medical agent containing the therapeutically effective amount of the PRO polypeptide having a pharmaceutically acceptable carrier and its agonist or antagonist are provided. And an anti-PRO antibody is also provided.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a mechanism for enhancing security and improving convenience of operation of a system in processing medical information.  &lt;P&gt;SOLUTION: This medical system includes a user terminal 10 for processing medical information and a storage means 30 of the medical information. The user terminal 10 reads out identification information of a mobile medium, detects operation, and records the identification information in association with the operation when the operation is detected, and does not accept the operation from the user when the mobile medium is not detected, and accepts the operation when the mobile medium is detected. Thereby, even when a third party inputs after the user of the mobile medium, uses, and then leaves in the middle, the third party can not operate it when the third party does not have the mobile medium. When the third party has his or her own mobile medium, the third party can operate it but the user is recorded as the third party who uses the user terminal. Therefore, it can be prevented from being recorded that the user who finishes makes an input.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PURPOSE: A method and an apparatus for supporting image diagnosis using medical images, and an image diagnosis system for performing the same are provided to analyze ultrasonic images by acquiring electronic medical records of a patient or other patients similar to patient&#39;s current condition. CONSTITUTION: A data receiving part(110) receives medical images and electronic medical records about the current condition of a patient. An electronic medical record acquisition unit(120) acquires an image analysis profile used for each of image analysis modes. An image analysis unit(130) analyzes the medical images. A diagnosis image generating unit(140) creates a plurality of diagnosis images corresponding to the respective image analysis modes. A display control unit(150) implements control for the created diagnosis images to be simultaneously displayed on the screen of an interface unit. An update unit(160) updates electronic medical records about the patient saved in an electronic medical record database.
PCT No. PCT/JP95/00280 Sec. 371 Date Aug. 23, 1996 Sec. 102(e) Date Aug. 23, 1996 PCT Filed Feb. 24, 1995 PCT Pub. No. WO95/23150 PCT Pub. Date Aug. 31, 1995A compound of the formula:    &lt;IMAGE&gt;  [I]  wherein R1 is a hydrogen atom or a lower alkyl group, R2 is a hydrogen atom or a negative charge, R3 is a hydrogen atom or a lower alkyl group, Ar is a phenyl group, a naphthyl group or a group of:  bond, -NHSO2- or the like, and Het is a pyrrolinyl group, a 1,4-diazabicyclo[2.2.2]octanyl group or the like which may be substituted with a hydroxyl group, a carbamoyl lower alkyl group or the like) which may be substituted with a lower alkyl group, a lower alkylsulfamoyl group or the like which may be substituted with a hydroxyl group, a di-lower alkylsulfonyl group or the like; a hydroxyl group; a di-lower alkylsulfamoyl group or the like, each of A1, A2 and A3 is a single bond or a lower alkylene group which may be substituted with a lower alkyl group, a lower alkylsulfamoyl group or the like which may be substituted with a hydroxyl group, a di-lower alkylsulfamoyl group or the like; a pyridyl group or a pyridino group; and W is a sulfur atom, a single bond; or a pharmaceutically acceptable salt or ester; a process for its production and an antibacterial agent containing it as an active ingredient.
A chatbot capable of empathic engagement with a user is disclosed. An identified trend in a user&#39;s mood or goals between a first time and a second time can be associated with open input (e.g., open text string input) from the user. As the user&#39;s mood or goals continue to be tracked, a subsequent trend can be identified that is the same as, similar to, different from, or opposite to the first identified trend. The user can then be automatically engaged based on the open input associated with the first identified trend. In an example, a user may input thoughts or reasons why they have been having a positively trending mood over a duration of time. The chatbot can then repeat or otherwise use those same thoughts or reasons to engage the user empathically when the chatbot detects that the user is experiencing a negatively trending mood.
Furuncle is acute suppurative inflammation caused by hair follicle or sebaceous gland, is mostly found on the face and limb ends with small sizes but deep roots, and is of a nail shape. Firstly, a small head is found on the top mostly, skin on the periphery of the head is hard and itching, and chill and fever and dizziness accompany. The furuncle spreads fast, the situation of &#39;carbuncle complicated by septicemia&#39; is taken as the most emergent condition and should be treated as early as possible if dark depression is seen on the furuncle top, blurred mind, high fever and other symptoms are found. Carbuncle is formed by fusing several furuncles together, and is mostly seen on neck and back. At first, only a head is found, and skin on the periphery of the head is red and swollen, and the red and swelling range is enlarged, and a plurality of heads occur, pains become intense, and high-fever, chill, headache, dizziness and other symptoms accompany. The invention provides a secret prescription prepared by dandelion and other traditional Chinese medicaments, and an up-to-date treatment scheme is creatively invented successfully by practice on the basis of repeated researches and clinical observations, sterilization and toxicity removal is the creative treatment method for treating malignant furuncle. The prescription can be used for quickly killing viruses and bacteria infection, and stopping root of the malignant furuncle from spreading.
Use of avarol (I) (or a deriv.), as antioxidant and inhibitor of enzymes involved in synthesis of prostaglendins and leukotrienes, is new. USE/ADVANTAGE - (I) is described in DE3427383. Derivs. are described in US4946869. They can be used in treatment of inflammatory systemic disorders and skin disorders, esp. in treatment of rheumatic diseases, autoimmune diseases, Psoriasis vulgaris, atopic dermatitis, Crohn&#39;s disease, colitis ulcerosa and inflammation of skin, mucous membranes and the associated blood vessel systems.